Skip to content Skip to footer

OUR MISSION

Accelerating the Discovery, Development & Production of Life-Saving Drugs & Devices.

We invest, acquire and partner with life sciences companies to build integrated systems that support collaboration, data management and analysis, and end-to-end process optimization.

Biologics & Medical Devices Class III

Revolutionising treatments and cures with more targeted, effective and personalised medicine and devices

ISO, GLP & GMP Certified

Seamlessly enabling collaboration between our ecosystem of facilities to promote safer and quality molecules

+ 0

YEARS OF EXPERIENCE

Our directors and advisory team consists of veteran executives with over 200 years of combined experience in biotechnological and pharmaceutical operations, business valuation, finance, taxes/audit, acquisitions and IPOs.

about mkb biopharma

What makes us different

Streamlined Processes and Automated Growth

We help acquired companies streamline their operations, leading to faster and more efficient drug and medical device development and production. By optimizing processes, as well as improving supply chain and logistics, we reduce costs, improve quality, and accelerate time-to-market. This enables companies to better meet demand, reduce lead times, and capitalize on new growth opportunities.

Access to Competencies and Scalable Capacities

Acquired companies gain access to expert competencies in research, development, production, and medical device manufacturing through MKB Biopharma. Additionally, MKB Biopharma's scalable capacities and flexible production allow companies to quickly respond to changing demand, reduce lead times, and maintain high-quality standards.

Systemizing Growth and Unlocking Opportunities

We help acquired companies systemize growth by establishing standardized procedures that ensure consistent, sustainable expansion. In addition, we help unlock opportunities by providing access to new markets, technologies, and research.

Accelerating Drug and Medical Device Lifecycle

Accelerating the drug and medical device lifecycle by helping acquired companies identify new growth opportunities and bring products to market more quickly. This results in increased revenue, market share, and improved patient outcomes, ultimately saving more lives.

who are we

our approach

MKB Biopharma is a life science consortium that specialises in investing & acquiring SMEs who doesn’t have an exit plan or that have hit a plateau and need support in their next growth phase. Our  approach is centered around fostering synergic collaboration and innovation to accelerate growth, improve patient outcomes, providing strategic support and facilitate mergers and partnerships opportunities to stay ahead of the competition.

Leveraging Cutting-Edge Technologies

Leveraging cutting-edge technologies to help our acquired companies stay ahead of the competition. By partnering with us, companies gain access to our network of industry experts and innovative processes, resulting in faster development, higher-quality products, and ultimately, better patient outcomes.

Fine-Tuning Procedures and Growing Core Competencies

Surrounding our acquired companies with the support, shared services, and operational guidance they need to thrive in the constantly evolving life science industry. We work collaboratively with them to fine-tune procedures, grow core competencies, and develop an independent mindset, resulting in a shared vision of excellence and faster results for our companies.

Removing Limitations and Maximizing Time

By partnering with us, acquired companies can remove limitations and focus on their core competencies. We provide support and guidance, including access to our network of experts and innovative processes, enabling companies to maximize their time and resources to focus on what they do best - developing innovative therapies and medical devices that improve patient outcomes.

Building a Strong Ecosystem for Accelerated Growth

MKB Biopharma's approach is centered around fostering an ecosystem that is exponentially greater than the sum of its individual parts. By partnering with us, acquired companies gain access to our network of experts, technologies, and innovative processes, enabling faster development, higher-quality products, and better patient outcomes. Our collaborative approach leads to a shared vision of excellence and accelerated growth for our companies.

Explore More

Leveraging Cutting-Edge Technologies

Leveraging cutting-edge technologies to help our acquired companies stay ahead of the competition. By partnering with us, companies gain access to our network of industry experts and innovative processes, resulting in faster development, higher-quality products, and ultimately, better patient outcomes.

Fine-Tuning Procedures and Growing Core Competencies

Surrounding our acquired companies with the support, shared services, and operational guidance they need to thrive in the constantly evolving life science industry. We work collaboratively with them to fine-tune procedures, grow core competencies, and develop an independent mindset, resulting in a shared vision of excellence and faster results for our companies.

Removing Limitations and Maximizing Time

By partnering with us, acquired companies can remove limitations and focus on their core competencies. We provide support and guidance, including access to our network of experts and innovative processes, enabling companies to maximize their time and resources to focus on what they do best - developing innovative therapies and medical devices that improve patient outcomes.

Building a Strong Ecosystem for Accelerated Growth

MKB Biopharma's approach is centered around fostering an ecosystem that is exponentially greater than the sum of its parts. By partnering with us, acquired companies gain access to our network of experts, technologies, and innovative processes, enabling faster development, higher-quality products, and better patient outcomes. Our collaborative approach leads to a shared vision of excellence and accelerated growth for our companies.

Explore More

Join our Bioleader Ecosystem

 
MKB Biopharma’s Bioleaders ecosystem is a community of exceptional companies that share a common goal of driving innovation and excellence in the life science industry. As members of the ecosystem, our Bioleaders have access to a vast network of industry experts, cutting-edge technology, and innovative processes that allow them to accelerate their growth and achieve unparalleled success. Our ecosystem is made up of recognised experts in their fields, each running their businesses independently, managing their people, culture, and business as they always have. We are here to promote agility and thought leadership, and our Bioleaders are free to continuously thrive through unmatched patients outcomes. By joining our ecosystem, our Bioleaders become part of a family committed to driving meaningful change and creating a brighter future for the life science industry.

Latest Research

Our Latest Case Studies

Contact Us For Excellent Service

Meet Our leadership Team

Board of Directors

Our board of directors comprises a team of successful and seasoned experts with a proven track record of completing over 30 billion CHF worth of transactions throughout our careers. With over 200 years of combined experience, we bring a unique blend of investing and operating skills to the table. Our focus is on providing invaluable guidance to our portfolio companies, ensuring their success and preserving their legacy as they continue to grow. We facilitate smooth partial or full exits for our companies, providing guidance post-acquisition to ensure a seamless transition into the next phase of their journey. Get to know the exceptional individuals behind MKB Biopharma.

Kari Sarvanto

Former CEO & Chairman of Primex Pharmaceuticals

CHAIRMAN

Richard Groenendijk

Partner at Remora Biotech, Expert CFO in VC/PE/Family Offices & Investor Relations

FINANCE DIRECTOR

Petra Egger

Legal Director at Oculis, former Head of Legal & Compliance at Alcon and Novartis

LEGAL DIRECTOR

Boris Mokabo

Founding Principal & CEO at MKB Biopharma, RE & Business Transactions Expert

FOUNDING DIRECTOR

Dr Matteo Di Padova

Former Director at Johnson and Johnson, and Ex Director at Jassen Pharmaceuticals

ACCOUNTING & OPERATION DIRECTOR

Dr Markus Christen

Former Chairman at Biovolution, Ex Global Head of Strategy & Business Dev at Novartis

STRATEGY & M&A DIRECTOR

Paul Palmer

Expert in GMP, GDP, CGP & GLP, Audited for BMS Labs, Novartis, Generics Uk, Fisher Clinical Services, Biogen Idec.

INDUSTRY EXPERT - QUALITY & COMPLIANCE DIRECTOR

Dr Daniela Drago

Former Director of Regulatory Affairs at Roche, Vifor Pharma & Aurion Biotech. Ex Professor at George Washington University, Fellow TOPRA & FRAPS

REGULATORY AFFAIRS & DRUG DEVELOPMENT DIRECTOR

there is a better way

Your Growth Start Here

    Boris Mokabo
    Boris Mokabo

    Founding Principal & CEO - MKB Biopharma

    "We are passionate about harnessing the power of breakthrough science and cutting-edge technology to facilitate the production of life saving drugs. We offer a unique opportunity to life-science business owners who lack the ability to scale operations. There’s a better way to grow your business. Get in touch with us if you’re ready to do things differently."

    Subscribe & Get Updates

    Quick Links

    Contact Info

    Copyright © 2023 MKB Biopharma – All Rights Reserved.